简体中文
繁體中文
English
Pусский
日本語
ภาษาไทย
Tiếng Việt
Bahasa Indonesia
Español
हिन्दी
Filippiiniläinen
Français
Deutsch
Português
Türkçe
한국어
العربية
Abstract:"We anticipate few if any delays in delivering results to customers," uBiome told its clients in an email.
uBiome has resumed processing its Explorer test, the company told customers on Thursday.
The company had to stop processing lab samples on July 10 after laying off its lab director, Susan Zneimer. She has since been reinstated as lab director, uBiome told customers on Thursday
Founded in 2012, uBiome raised $105 million from investors on the promise of exploring the “forgotten organ” that is the microbiome. In April, the FBI raided uBiome's headquarters, reportedly over the company's billing practices.
Click here for more BI Prime stories.
uBiome is back to running its only lab test, the troubled startup told customers on Thursday, a week after it was forced to stop running the test after laying off key employees.
The company had to stop processing lab samples on July 10 after cutting its lab director, Susan Zneimer. She has since been brought back on, according to an email sent to customers that uBiome shared with Business Insider.
Lab testing has resumed for the company's Explorer test, a direct-to-consumer product that tells users what microbes are in their guts. The test costs $89 and uses a small sample of a person's poop.
“You may be aware that last week we temporarily paused processing Explorer samples while we executed an organizational change at the company,” uBiome said in the email. “We are pleased to inform you that Dr. Susan Zneimer will continue as uBiome's Lab Director and we have resumed processing Explorer samples. We anticipate few if any delays in delivering results to customers.”
Zneimer was let go as part of a round of layoffs in which uBiome cut about half its workforce. The startup is working to find a path forward after the FBI raided the startup in April. Following the raid, the company suspended sales of two doctor-ordered tests, SmartGut and SmartJane.
Read more: uBiome convinced Silicon Valley that testing poop was worth $600 million. Then the FBI came knocking. Here's the inside story.
Its cofounders and co-CEOs departed, and uBiome has been adding executives and board members who have experience with bankruptcies and turning around troubled companies.
Founded in 2012, uBiome raised $105 million from investors and achieved a $600 million valuation on the promise of helping people understand the bacteria in their bodies, called the microbiome.
Click here to read more about uBiome.
Here's the letter sent to customers:
Dear uBiome Customers,
You may be aware that last week we temporarily paused processing ExplorerTM samples while we executed an organizational change at the company.
We are pleased to inform you that Dr. Susan Zneimer will continue as uBiome's Lab Director and we have resumed processing Explorer samples.
We anticipate few if any delays in delivering results to customers.
We remain committed to our customers and to the integrity of our product. We thank you for your patience.
Please do not hesitate to reach out to us at support@ubiome.com if you have questions.
The uBiome Team
Disclaimer:
The views in this article only represent the author's personal views, and do not constitute investment advice on this platform. This platform does not guarantee the accuracy, completeness and timeliness of the information in the article, and will not be liable for any loss caused by the use of or reliance on the information in the article.
Jen Gotch, founder of accessories and stationery brand ban.do, said sometimes the best thing you can do is just say yes and figure it out later.
After a historic oil price rout, energy markets appear set to recover. Morgan Stanley says these 12 oil and gas stocks will benefit most.
Diane Daley spent over two decades at Citigroup, eventually serving as a managing director and the head of finance and risk management infrastructure.
Of the 100 largest US metro areas, Zillow found that 26 saw a month-over-month decrease in median listing price, ranging from 0.1% to 3.3%.